SCHEMBL208468

SCHEMBL208468

[CH2]C(=O)NS(=O)(=O)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 2/20 0.36
GRIA1 P42261 3/20 0.36
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21872080 0.76 P4HTM (0.41) P4HTMGRIA1CA14
SCHEMBL208469 0.76 GRIA1 (0.37) P4HTMGRIA1CA14
SCHEMBL84561 0.74 ALDH1A1 (0.42) P4HTMGRIA1CA14
SCHEMBL17779025 0.72 P4HTM (0.35) P4HTMGRIA1
SCHEMBL24178124 0.70 ALDH1A1 (0.34) P4HTMGRIA1CA14
SCHEMBL13366726 0.70 GRIA1 (0.38) P4HTMGRIA1
SCHEMBL10227596 0.70 CHRNB2 (0.36) P4HTMGRIA1
SCHEMBL17774458 0.70 ALDH1A1 (0.39) P4HTMGRIA1
SCHEMBL208790 0.69
SCHEMBL21104353 0.69 CA2 (0.39) P4HTMGRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431370-A1 Monoacylated 1,2-diaminocycloalkanes DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2012-03-21 EP disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-8058440-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-15 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-7935824-B2 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-05-03 US disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 US disclosed
EP-2266991-A2 Process for producing thiazole derivative Daiichi Sankyo Company, Limited (JP) 2010-12-29 EP disclosed
EP-2266992-A2 Process for producing thiazole derivative Daiichi Sankyo Company, Limited (JP) 2010-12-29 EP disclosed
US-20060004009-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
US-20040122063-A1 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-24 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID PAH, CA4, TET2 P4HTM 282/4885GRIA1 2484/4885CA14 48/4885
US-20060004009-A1 Ethylenediamine derivatives F2, ECE1, MLLT1 P4HTM 1907/4885GRIA1 2822/4885CA14 2213/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R P4HTM 3829/4885GRIA1 1832/4885CA14 3993/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R P4HTM 3829/4885GRIA1 1832/4885CA14 3993/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R P4HTM 3829/4885GRIA1 1832/4885CA14 3993/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 P4HTM 1427/4885GRIA1 2057/4885CA14 1350/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R P4HTM 3415/4885GRIA1 1820/4885CA14 4017/4885
US-20040122063-A1 Ethylenediamine derivatives ECE1, F2, ECE2 P4HTM 2364/4885GRIA1 2497/4885CA14 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.